Voxelotor is approved in the United States and the European Union for the treatment of sickle cell disease.
United States
- Approval Date: November 2019
- Brand Name: Oxbryta®
- Indication: Voxelotor is approved for the treatment of sickle cell disease in adult and pediatric patients aged 12 years and older.
European Union
- Approval Date: May 2021
- Brand Name: Oxbryta®
- Indication: Voxelotor is approved for the treatment of sickle cell disease in adult and pediatric patients aged 12 years and older.
